"Anti-Allergic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)
| Descriptor ID |
D018926
|
| MeSH Number(s) |
D27.505.954.016
|
| Concept/Terms |
Anti-Allergic Agents- Anti-Allergic Agents
- Agents, Anti-Allergic
- Anti Allergic Agents
- Anti-Allergy Drugs
- Anti Allergy Drugs
- Drugs, Anti-Allergy
- Antiallergy Agents
- Agents, Antiallergy
- Antiallergic Drugs
- Drugs, Antiallergic
- Antiallergics
- Anti-Allergics
- Anti Allergics
- Antiallergic Agents
- Agents, Antiallergic
|
Below are MeSH descriptors whose meaning is more general than "Anti-Allergic Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Allergic Agents".
This graph shows the total number of publications written about "Anti-Allergic Agents" by people in this website by year, and whether "Anti-Allergic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 3 | 0 | 3 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 3 | 0 | 3 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Allergic Agents" by people in Profiles.
-
Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances. Allergy. 2023 02; 78(2):389-401.
-
Biologics for the Use in Chronic Spontaneous Urticaria: When and Which. J Allergy Clin Immunol Pract. 2021 03; 9(3):1067-1078.
-
Sources of exposure to urinary phthalates among couples undergoing infertility treatment. Int J Hyg Environ Health. 2020 08; 229:113567.
-
Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study. J Am Acad Dermatol. 2018 04; 78(4):793-795.
-
Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2017 Oct; 31(10):1715-1721.
-
Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017 Apr; 72(4):519-533.
-
Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies. Ann Allergy Asthma Immunol. 2016 10; 117(4):370-377.e1.
-
Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2016 Feb; 137(2):474-81.
-
How omalizumab came to be studied as a therapy for chronic spontaneous/idiopathic urticaria. J Allergy Clin Immunol Pract. 2015 Jul-Aug; 3(4):648.
-
Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Eye Contact Lens. 2014 Sep; 40(5):289-96.